The primary objective of this effort is to provide supporting research, identify key issues, and convene appropriate subject matter experts to help inform major initiatives for process improvement and regulatory science related to FDA commitments under the 2018 reauthorization of the Prescription Drug
User Fee Act (PDUFA VI) and the 21st Century Cures Act legislation.